[Use of antilymphocyte globulin in autoimmune nervous system diseases]
- PMID: 88390
[Use of antilymphocyte globulin in autoimmune nervous system diseases]
Abstract
The pathogenetic bases for the indication of immunosuppression in multiple sclerosis are represented in a survey, rested upon experiences in the clinical compatability test of AHLG Dessau. The knowledge gained in animal experiments and epidemiology in recent years is considered and problems of membrane, slow-virus hypothesis, genetic problems and changes of immunoglobulins and lymphocytes are critically referred to.
Similar articles
-
The evidence justifying immunosuppression therapy in multiple sclerosis.Proc R Soc Med. 1977 Dec;70(12):871-4. doi: 10.1177/003591577707001214. Proc R Soc Med. 1977. PMID: 202967 Free PMC article. Review. No abstract available.
-
[Antilymphocyte globulin in intensive immunosuppression in patients with multiple sclerosis].Postepy Hig Med Dosw. 1978 Jul-Aug;32(4):513-22. Postepy Hig Med Dosw. 1978. PMID: 724575 Polish. No abstract available.
-
[Compatibility of antihuman lymphocyte globulin (AHLG). Possible side effects and complications].Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(1):37-52. Folia Haematol Int Mag Klin Morphol Blutforsch. 1979. PMID: 88389 German.
-
[Initial results of clinical compatibility testing of antihuman lymphocyte globulin (AHLG-Dessau)].Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;98(1):31-45. Folia Haematol Int Mag Klin Morphol Blutforsch. 1972. PMID: 4118779 German. No abstract available.
-
[Clinical picture and therapy of multiple sclerosis].Wien Med Wochenschr. 1972 Mar 4;122(10):129-34. Wien Med Wochenschr. 1972. PMID: 4334261 Review. German. No abstract available.